KC
EIDX

Kellner Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Kellner Capital’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,357
Closed -$3.47M – 38
2020
Q4 		$3.47M Buy
+26,357
New +$2.33M 1.83% 17

Kellner Capital's EIDX Position: Q1 2021 in Review

Kellner Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 26,357 shares — an estimated $3.47M sold.

Kellner Capital first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $3.47M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Kellner Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Kellner Capital sold 26,357 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.47M.
  • Kellner Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Kellner Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $3.47M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Kellner Capital's 13F filing for Q1 2021, filed 10 May 2021.